<div id="readability-page-1"><p>Bruker (NASDAQ:BRKR - Get Free Report) is expected to be issuing its  Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Bruker to post earnings of $0.65 per share and revenue of $964.6130 million for the quarter. Parties are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.</p><p>Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business's quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS.  On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year. </p><h2>Bruker Stock Down 0.2%</h2><p>Shares of BRKR opened at $42.56 on Thursday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. The company has a 50-day simple moving average of $47.98 and a 200-day simple moving average of $40.48. Bruker has a 52 week low of $28.53 and a 52 week high of $57.92. The firm has a market capitalization of $6.47 billion, a P/E ratio of -266.00, a P/E/G ratio of 5.61 and a beta of 1.19. </p><h2>Analysts Set New Price Targets</h2><p>A number of brokerages have commented on BRKR. Citigroup raised their price objective on Bruker from $40.00 to $53.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, January 16th. TD Cowen  reaffirmed a &#34;hold&#34; rating on shares of Bruker in a research report on Wednesday, January 7th. Wells Fargo &amp; Company boosted their price target on shares of Bruker from $48.00 to $55.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, December 15th. UBS Group raised their price objective on shares of Bruker from $40.00 to $43.00 and gave the stock a &#34;neutral&#34; rating in a report on Tuesday, November 4th. Finally, The Goldman Sachs Group started coverage on shares of Bruker in a research report on Tuesday, December 9th. They issued a &#34;sell&#34; rating and a $40.00 price target for the company. One investment analyst  has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have assigned  a Hold rating and two have assigned  a Sell rating to the company. According to data from MarketBeat, Bruker presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $53.71.</p><p><b>View Our Latest Research Report on Bruker</b></p><h2>Insider Transactions at Bruker</h2><p>In other Bruker news, VP Mark Munch sold 7,000 shares of the business's stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president owned 128,443 shares of the company's stock, valued at approximately $7,064,365. The trade was a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Insiders own  27.30% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Allworth Financial LP increased its position in  Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock valued at $29,000 after acquiring an additional 257 shares in the last quarter.  Armistice Capital LLC acquired a new stake in shares of  Bruker in the third quarter valued at approximately $321,000.  Dark Forest Capital Management LP raised its position in  Bruker by 256.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 71,779 shares of the medical research company's stock worth $2,332,000 after purchasing an additional 51,614 shares during the last quarter.  XTX Topco Ltd acquired a new position in  Bruker during the 3rd quarter worth $589,000.  Finally, Voloridge Investment Management LLC lifted its holdings in  Bruker by 408.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 831,834 shares of the medical research company's stock worth $27,026,000 after buying an additional 668,078 shares in the last quarter. Institutional investors and hedge funds own  79.52% of the company's stock. </p><h2>Bruker Company Profile</h2> (Get Free Report)<p>Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.  </p><p>Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.  </p><p>In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Bruker</li><li>The day the gold market broke</li><li>Buy this Gold Stock Before May 2026</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li><li>New gold price target</li><li>Trump Planning to Use Public Law 63-43: Prepare Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QlJLUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QlJLUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bruker Right Now?</h2><p>Before you consider Bruker, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.</p><p>While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BRKR

SBIO

<p>Bruker (NASDAQ:BRKR) is set to release its Q4 2025 earnings on February 12, with analysts expecting earnings of $0.65 per share and revenue of $964.61 million. The company reported $0.45 EPS in its last quarter, exceeding estimates. Bruker shares opened at $42.56, with a market cap of $6.47 billion. Analysts have varied ratings, with a consensus rating of "Moderate Buy" and an average price target of $53.71. Recent insider transactions and institutional investments have also been noted, with insiders owning 27.30% of the stock.</p>

Bruker (BRKR) to Release Quarterly Earnings on Thursday